Josh Ludwig Discusses Key Themes at ISCT 2023 Paris Meeting
The future of cell and gene therapy manufacturing is poised for transformative advancements, driven by key themes that aim to enhance scalability, efficiency, and safety. One crucial theme is automation and process standardization. As the demand for these therapies grows, there is a pressing need to streamline and automate manufacturing processes to ensure consistency and reproducibility. By employing robotics and advanced bioreactor systems, researchers can optimize production workflows, reduce human errors and accelerate the manufacturing timeline, ultimately making these treatments more accessible to a broader patient population.
Josh Ludwig, global commercial director of ScaleReady, believes the cell and gene therapy industry should first simplify, then standardize and finally automate. Josh discusses the key industry themes and how to approach automate in a recent conversation at ISCT 2023 in Paris.
Are you ready to scale?
Let’s talk more about how ScaleReady can advance your cell and gene therapy research and manufacturing with ingenious efficiency.
